MorphoSys AG is a biopharmaceutical company based in Germany that develops antibodies for treating cancer and autoimmune diseases. Its products include Tafasitamab for B cell malignancies, Pelabresib for treating myelofibrosis, Felzartamab for anti-PLA2R-positive membranous nephropathy, and CPI-0209 for promoting anti-tumor activity. MorphoSys AG has partnerships with other pharmaceutical companies to develop and distribute its products in various regions of the world.